Registration Number
0225U003077,
(0122U000119)
, R & D reports
Title
Development of a strategy for the diagnosis, treatment and prediction of chronic heart failure of ischemic origin on the background of metabolic disorders
popup.stage_title
Розробка стратегії діагностики, лікування та прогнозування перебігу хронічної серцевої недостатності ішемічного ґенезу на тлі метаболічних порушень
Head
Kravchun Pavlo Н., д.мед.н.
Registration Date
14-05-2025
Organization
Kharkiv National Medical University
popup.description1
Іmproving the effectiveness of diagnosis and treatment of chronic heart failure in patients with coronary heart disease on the background of concomitant obesity and type 2 diabetes mellitus based on the determination of humoral parameters: galectin-3, nesfatin-1, Gas6 protein, cathestatin, NTproBNP, parameters , assessment of their prognostic value in the course of chronic heart failure of ischemic origin in the presence of metabolic disorders
popup.description2
The following were established: the activity of galectin-3, nesfatin-1, catestatin and NTproBNP in blood plasma in accordance with changes in lipid and carbohydrate profile parameters, changes in psycho-emotional state and quality of life of patients with chronic heart failure of ischemic genesis depending on the presence of concomitant metabolic disorders. The presence and nature of relationships between cardiohemodynamic indicators, markers of adipogenesis, systemic immune inflammation, fibrogenesis, cardiovascular remodeling and metabolic disorders depending on the functional class of heart failure in patients with ischemic heart disease on the background of concomitant type 2 diabetes mellitus and obesity were proven; the effect of standard combined treatment of patients with coronary heart disease and chronic heart failure on increasing exercise tolerance, improving quality of life, a significant decrease in proatherogenic lipid fractions, a decrease in insulin resistance, a significant decrease in the concentration of the fibrosis marker galectin-3, a decrease in NT-pro-BNP content by 52.5%, and an improvement in the clinical condition of patients.
Product Description
popup.authors
Babadzhan Volodymyr D.
Borovyk Kateryna M.
Kadykova Olha Ih.
Kravchun Pavlo H.
Ryndina Nataliia H.
popup.nrat_date
2025-05-14
